Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Development and Validation of a Combined Hypoxia and Immune Prognostic Classifier for Head and Neck Cancer.

Brooks JM, Menezes AN, Ibrahim M, Archer L, Lal N, Bagnall CJ, von Zeidler SV, Valentine HR, Spruce RJ, Batis N, Bryant JL, Hartley M, Kaul B, Ryan GB, Bao R, Khattri A, Lee SP, Ogbureke KUE, Middleton G, Tennant DA, Beggs AD, Deeks J, West CML, Cazier JB, Willcox BE, Seiwert TY, Mehanna H.

Clin Cancer Res. 2019 Jun 10. pii: clincanres.3314.2018. doi: 10.1158/1078-0432.CCR-18-3314. [Epub ahead of print]

PMID:
31182433
2.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE.

Ann Oncol. 2019 Jun 5. pii: mdz171. doi: 10.1093/annonc/mdz171. [Epub ahead of print] No abstract available.

PMID:
31168601
3.

Prognostic value of pre-treatment CT texture analysis in combination with change in size of the primary tumor in response to induction chemotherapy for HPV-positive oropharyngeal squamous cell carcinoma.

Miller TA, Robinson KR, Li H, Seiwert TY, Haraf DJ, Lan L, Giger ML, Ginat DT.

Quant Imaging Med Surg. 2019 Mar;9(3):399-408. doi: 10.21037/qims.2019.03.08.

4.

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).

Pai SI, Faivre S, Licitra L, Machiels JP, Vermorken JB, Bruzzi P, Gruenwald V, Giglio RE, Leemans CR, Seiwert TY, Soulieres D.

J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.

5.

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.

Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE.

Ann Oncol. 2019 Feb 1;30(2):297-302. doi: 10.1093/annonc/mdy522.

PMID:
30481287
6.

Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D.

Science. 2018 Oct 12;362(6411). pii: eaar3593. doi: 10.1126/science.aar3593. Erratum in: Science. 2019 Mar 1;363(6430):.

7.

Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012.

Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQM, Haddad R.

Br J Cancer. 2018 Jul;119(2):153-159. doi: 10.1038/s41416-018-0131-9. Epub 2018 Jun 29.

PMID:
29955135
8.

Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.

Foster CC, Melotek JM, Brisson RJ, Seiwert TY, Cohen EEW, Stenson KM, Blair EA, Portugal L, Gooi Z, Agrawal N, Vokes EE, Haraf DJ.

Oral Oncol. 2018 May;80:16-22. doi: 10.1016/j.oraloncology.2018.03.008. Epub 2018 Mar 16.

PMID:
29706184
9.

Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of in vitro expanded populations in head and neck cancer.

Ren L, Matsuda T, Deng B, Kiyotani K, Kato T, Park JH, Seiwert TY, Vokes EE, Agrawal N, Nakamura Y.

Oncotarget. 2017 Dec 19;9(3):3805-3814. doi: 10.18632/oncotarget.23454. eCollection 2018 Jan 9.

10.

Role of dental hardware in oral cavity squamous cell carcinoma in the low-risk nonsmoker nondrinker population.

Yesensky JA, Hasina R, Wroblewski KE, Bellairs J, Gooi Z, Saloura V, Cipriani NA, Vokes EE, Portugal LG, Seiwert TY, Blair ED, Agrawal N.

Head Neck. 2018 Apr;40(4):784-792. doi: 10.1002/hed.25059. Epub 2018 Jan 22.

PMID:
29356169
11.

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK.

J Clin Invest. 2017 Aug 1;127(8):2930-2940. doi: 10.1172/JCI91190. Epub 2017 Jun 26.

12.

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.

Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, Handa M, Tomassini JE, McClanahan T.

Clin Cancer Res. 2017 Jun 15;23(12):3158-3167. doi: 10.1158/1078-0432.CCR-16-1761.

13.

Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

Moskovitz JM, Moy J, Seiwert TY, Ferris RL.

Oncologist. 2017 Jun;22(6):680-693. doi: 10.1634/theoncologist.2016-0318. Epub 2017 May 15. Review.

14.

How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?

Szturz P, Seiwert TY, Vermorken JB.

J Clin Oncol. 2017 Jul 10;35(20):2229-2231. doi: 10.1200/JCO.2016.71.8072. Epub 2017 May 4. No abstract available.

PMID:
28471725
15.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R.

J Clin Oncol. 2017 May 10;35(14):1542-1549. doi: 10.1200/JCO.2016.70.1524. Epub 2017 Mar 22.

16.

Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays.

Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, McDonald N, Niu N, Benhamed S, Tuteja JH, Seiwert TY, White KP, McNerney ME, Fitzpatrick C, Wang YL, Furtado LV, Segal JP.

J Mol Diagn. 2017 Jan;19(1):43-56. doi: 10.1016/j.jmoldx.2016.07.012. Epub 2016 Nov 9.

PMID:
27836695
17.

Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.

Rieke DT, Ochsenreither S, Klinghammer K, Seiwert TY, Klauschen F, Tinhofer I, Keilholz U.

Oncotarget. 2016 Nov 15;7(46):75379-75393. doi: 10.18632/oncotarget.12211.

18.

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY.

J Clin Oncol. 2016 Nov 10;34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478. Epub 2016 Sep 30.

PMID:
27646946
19.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM.

Cancer. 2016 Dec 15;122(24):3803-3811. doi: 10.1002/cncr.30256. Epub 2016 Aug 15.

20.

Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.

Seiwert TY, Melotek JM, Blair EA, Stenson KM, Salama JK, Witt ME, Brisson RJ, Chawla A, Dekker A, Lingen MW, Kocherginsky M, Villaflor VM, Cohen EE, Haraf DJ, Vokes EE.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):21-9. doi: 10.1016/j.ijrobp.2016.04.030. Epub 2016 May 7.

PMID:
27511844
21.

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.

Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, Cheng JD, Chow LQ.

Lancet Oncol. 2016 Jul;17(7):956-965. doi: 10.1016/S1470-2045(16)30066-3. Epub 2016 May 27.

PMID:
27247226
22.

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma.

Rolle CE, Tan YC, Seiwert TY, Vora S, Kanteti R, Hasina R, Carey GB, Surati M, Weichselbaum RR, Lingen MW, Vokes EE, Salgia R.

Oncotarget. 2017 Mar 21;8(12):18726-18734. doi: 10.18632/oncotarget.9640.

23.

Growth factor expression mediates resistance to EGFR inhibitors in head and neck squamous cell carcinomas.

Tepper SR, Zuo Z, Khattri A, Heß J, Seiwert TY.

Oral Oncol. 2016 May;56:62-70. doi: 10.1016/j.oraloncology.2016.03.008. Epub 2016 Mar 26.

PMID:
27086488
24.

Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.

Villaflor VM, Melotek JM, Karrison TG, Brisson RJ, Blair EA, Portugal L, De Souza JA, Ginat DT, Stenson KM, Langerman A, Kocherginsky M, Spiotto MT, Hannigan N, Seiwert TY, Cohen EE, Vokes EE, Haraf DJ.

Ann Oncol. 2016 May;27(5):908-13. doi: 10.1093/annonc/mdw051. Epub 2016 Feb 15.

PMID:
26884588
25.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

Dolly SO, Wagner AJ, Bendell JC, Kindler HL, Krug LM, Seiwert TY, Zauderer MG, Lolkema MP, Apt D, Yeh RF, Fredrickson JO, Spoerke JM, Koeppen H, Ware JA, Lauchle JO, Burris HA 3rd, de Bono JS.

Clin Cancer Res. 2016 Jun 15;22(12):2874-84. doi: 10.1158/1078-0432.CCR-15-2225. Epub 2016 Jan 19.

26.

HPV-Associated Head and Neck Cancer.

Vokes EE, Agrawal N, Seiwert TY.

J Natl Cancer Inst. 2015 Dec 9;107(12):djv344. doi: 10.1093/jnci/djv344. Print 2015 Dec.

PMID:
26656751
27.

Genetic Landscape of Human Papillomavirus-Associated Head and Neck Cancer and Comparison to Tobacco-Related Tumors.

Hayes DN, Van Waes C, Seiwert TY.

J Clin Oncol. 2015 Oct 10;33(29):3227-34. doi: 10.1200/JCO.2015.62.1086. Epub 2015 Sep 8. Review.

28.

Reply to s. Chakraborty et al.

Cohen EE, Kocherginsky M, Karrison T, Seiwert TY, Haraf DJ, Brockstein B, Vokes EE.

J Clin Oncol. 2015 Mar 10;33(8):968. doi: 10.1200/JCO.2014.59.6189. Epub 2015 Feb 9. No abstract available.

PMID:
25667282
29.

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.

Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, Watson S, Locati LD, Licitra L, Greco A, Pelosi G, Carcangiu ML, Lingen MW, Seiwert TY, Cohen EE.

Cancer Lett. 2015 Apr 10;359(2):269-74. doi: 10.1016/j.canlet.2015.01.024. Epub 2015 Jan 29.

PMID:
25641339
30.

Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes.

Keck MK, Zuo Z, Khattri A, Stricker TP, Brown CD, Imanguli M, Rieke D, Endhardt K, Fang P, Brägelmann J, DeBoer R, El-Dinali M, Aktolga S, Lei Z, Tan P, Rozen SG, Salgia R, Weichselbaum RR, Lingen MW, Story MD, Ang KK, Cohen EE, White KP, Vokes EE, Seiwert TY.

Clin Cancer Res. 2015 Feb 15;21(4):870-81. doi: 10.1158/1078-0432.CCR-14-2481. Epub 2014 Dec 9.

31.

Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing.

Seiwert TY.

J Clin Oncol. 2014 Dec 10;32(35):3914-6. doi: 10.1200/JCO.2014.57.9268. Epub 2014 Nov 3. No abstract available.

PMID:
25366683
32.

Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.

Das LC, Karrison TG, Witt ME, Muller C, Stenson K, Blair EA, Cohen EE, Seiwert TY, Haraf DJ, Vokes EE.

Ann Oncol. 2015 Jan;26(1):198-205. doi: 10.1093/annonc/mdu511. Epub 2014 Oct 30.

PMID:
25361984
33.

Impact of warm ischemia on phosphorylated biomarkers in head and neck squamous cell carcinoma.

Tower JI, Lingen MW, Seiwert TY, Langerman A.

Am J Transl Res. 2014 Oct 11;6(5):548-57. eCollection 2014.

34.

Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma.

Khattri A, Zuo Z, Brägelmann J, Keck MK, El Dinali M, Brown CD, Stricker T, Munagala A, Cohen EE, Lingen MW, White KP, Vokes EE, Seiwert TY.

Oral Oncol. 2015 Jan;51(1):53-8. doi: 10.1016/j.oraloncology.2014.08.014. Epub 2014 Sep 23.

PMID:
25255959
35.

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas.

Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker T, Brown C, Pugh TJ, Stojanov P, Cho J, Lawrence MS, Getz G, Brägelmann J, DeBoer R, Weichselbaum RR, Langerman A, Portugal L, Blair E, Stenson K, Lingen MW, Cohen EE, Vokes EE, White KP, Hammerman PS.

Clin Cancer Res. 2015 Feb 1;21(3):632-41. doi: 10.1158/1078-0432.CCR-13-3310. Epub 2014 Jul 23.

36.

Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.

Cohen EE, Karrison TG, Kocherginsky M, Mueller J, Egan R, Huang CH, Brockstein BE, Agulnik MB, Mittal BB, Yunus F, Samant S, Raez LE, Mehra R, Kumar P, Ondrey F, Marchand P, Braegas B, Seiwert TY, Villaflor VM, Haraf DJ, Vokes EE.

J Clin Oncol. 2014 Sep 1;32(25):2735-43. doi: 10.1200/JCO.2013.54.6309. Epub 2014 Jul 21.

37.

DNA repair biomarkers XPF and phospho-MAPKAP kinase 2 correlate with clinical outcome in advanced head and neck cancer.

Seiwert TY, Wang X, Heitmann J, Villegas-Bergazzi V, Sprott K, Finn S, O'Regan E, Farrow AD, Weichselbaum RR, Lingen MW, Cohen EE, Stenson K, Weaver DT, Vokes EE.

PLoS One. 2014 Jul 14;9(7):e102112. doi: 10.1371/journal.pone.0102112. eCollection 2014.

38.

Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.

Heitmann J, Geeleher P, Zuo Z, Weichselbaum RR, Vokes EE, Fetscher S, Seiwert TY.

Oral Oncol. 2014 Sep;50(9):825-31. doi: 10.1016/j.oraloncology.2014.06.004. Epub 2014 Jul 10.

PMID:
25017803
39.

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.

Seiwert TY, Fayette J, Cupissol D, Del Campo JM, Clement PM, Hitt R, Degardin M, Zhang W, Blackman A, Ehrnrooth E, Cohen EE.

Ann Oncol. 2014 Sep;25(9):1813-20. doi: 10.1093/annonc/mdu216. Epub 2014 Jun 13.

40.

A value framework in head and neck cancer care.

de Souza JA, Seiwert TY.

Am Soc Clin Oncol Educ Book. 2014:e304-9. doi: 10.14694/EdBook_AM.2014.34.e304.

41.

Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.

Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML.

Oncologist. 2013;18(8):965-70. doi: 10.1634/theoncologist.2013-0006. Epub 2013 Jul 30.

42.

EGFR-directed treatments in SCCHN.

Vokes EE, Seiwert TY.

Lancet Oncol. 2013 Jul;14(8):672-3. doi: 10.1016/S1470-2045(13)70215-8. Epub 2013 Jun 6. No abstract available.

PMID:
23746667
43.

Molecular pathways in head and neck cancer: EGFR, PI3K, and more.

Psyrri A, Seiwert TY, Jimeno A.

Am Soc Clin Oncol Educ Book. 2013:246-55. doi: 10.1200/EdBook_AM.2013.33.246. Review.

44.

Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.

Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, Khattri A, Keck M, McNerney ME, Longnecker R, Bieging K, Kocherginsky M, Alexander K, Salgia R, Lingen MW, Vokes EE, White KP, Cohen EE, Seiwert TY.

Oral Oncol. 2013 Jun;49(6):525-33. doi: 10.1016/j.oraloncology.2013.02.003. Epub 2013 Mar 13.

PMID:
23490885
45.

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.

Young NR, Liu J, Pierce C, Wei TF, Grushko T, Olopade OI, Liu W, Shen C, Seiwert TY, Cohen EE.

Mol Oncol. 2013 Jun;7(3):359-68. doi: 10.1016/j.molonc.2012.11.001. Epub 2012 Nov 14.

46.

A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.

Seiwert TY, Darga T, Haraf D, Blair EA, Stenson K, Cohen EE, Salama JK, Villaflor V, Witt ME, Lingen MW, Weichselbaum RR, Vokes EE.

Ann Oncol. 2013 Mar;24(3):769-76. doi: 10.1093/annonc/mds523. Epub 2012 Oct 26.

47.

Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.

Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, Vokes EE, Cohen EE.

Oral Oncol. 2012 Sep;48(9):887-92. doi: 10.1016/j.oraloncology.2012.03.020. Epub 2012 Apr 17.

PMID:
22513208
48.

mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.

Molinolo AA, Marsh C, El Dinali M, Gangane N, Jennison K, Hewitt S, Patel V, Seiwert TY, Gutkind JS.

Clin Cancer Res. 2012 May 1;18(9):2558-68. doi: 10.1158/1078-0432.CCR-11-2824. Epub 2012 Mar 12.

49.

A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck.

de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE.

Clin Cancer Res. 2012 Apr 15;18(8):2336-43. doi: 10.1158/1078-0432.CCR-11-2825. Epub 2012 Feb 27.

50.

Single sample expression-anchored mechanisms predict survival in head and neck cancer.

Yang X, Regan K, Huang Y, Zhang Q, Li J, Seiwert TY, Cohen EE, Xing HR, Lussier YA.

PLoS Comput Biol. 2012 Jan;8(1):e1002350. doi: 10.1371/journal.pcbi.1002350. Epub 2012 Jan 26. Erratum in: PLoS Comput Biol. 2014 May;10(5):e1003609.

Supplemental Content

Loading ...
Support Center